Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis

Table 3

Comparison of clinical outcomes pre- and posttherapy with Dupilumab.

	At baseline	At the end of observation period	value
Median (IQR) EASI at baseline	31 (25–40)	5 (1–10)	<0.0001
Median (IQR) DLQI at baseline	10 (10–25)	3 (1–5)	<0.0001
Median (IQR) NRS at baseline	10 (8–10)	2 (1–3)	<0.0001